Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC SODIUM AND MISOPROSTOL versus TRAVOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC SODIUM AND MISOPROSTOL versus TRAVOPROST.
DICLOFENAC SODIUM AND MISOPROSTOL vs TRAVOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Misoprostol is a synthetic prostaglandin E1 analog that replaces protective prostaglandins in the gastric mucosa, reducing gastric acid secretion and increasing mucus and bicarbonate production.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
Diclofenac sodium 50 mg/misoprostol 200 mcg orally twice daily with food for osteoarthritis and rheumatoid arthritis; diclofenac sodium 75 mg/misoprostol 200 mcg orally twice daily for rheumatoid arthritis.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Diclofenac: Terminal t1/2 ~1-2 h (short, requiring frequent dosing). Misoprostol: Terminal t1/2 ~20-40 min (rapidly de-esterified to active misoprostol acid, with acid t1/2 ~20-30 min).
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Diclofenac: ~65% renal (primarily as glucuronide conjugates, with <1% unchanged), ~35% biliary/fecal. Misoprostol: >80% renal as inactive metabolites.
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Category D/X
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."